M-14010 Free Prostate-Specific Antigen (f-PSA) Quantitative Test Kit

Clinical Significance: In patients with prostate cancer, the majority of PSA is in a bound state, resulting in a free PSA to total PSA ratio that is lower than that in healthy individuals or those with benign prostatic hyperplasia. Therefore, for men with elevated total PSA levels, measuring free PSA and calculating the free PSA to total PSA ratio can improve the specificity of prostate cancer screening and diagnosis.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Urology Departments: For improved specificity in screening and diagnosing prostate cancer by measuring both total PSA and free PSA levels.
Primary Care and Screening Programs: For routine screening of men with elevated total PSA levels, particularly those over 50 years old, to differentiate between prostate cancer and benign prostatic hyperplasia.
Diagnostic Laboratories: For comprehensive PSA testing to provide more accurate assessments of prostate health.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for precise cancer screening and management.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving cancer diagnostic capabilities and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer screening and management in low-resource settings.